Advertisement
Screener

Pluri Inc. (PLUR) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

2.3 / 5 stars · 29/62 Roast Me

Pluri Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

Pluri Inc. (PLUR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 9-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-05-14

  • Pluri Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2026-03-310.00%
10-Q · filed 2026-05-14
2025-12-310.00%
10-Q · filed 2026-02-12
2021-06-300.00%
10-K · filed 2021-09-13
2021-03-310.00%
10-Q · filed 2021-05-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
INTENSITY THERAPEUTICS, INC. (INTS)United States$0.013B-1.08
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)United States$0.013B-1.05
Passage BIO, Inc. (PASG)United States$0.015B-0.43
IN8BIO, INC. (INAB)United States$0.012B-0.76
DYADIC INTERNATIONAL INC (DYAI)United States$0.016B
BioCardia, Inc. (BCDA)United States$0.016B
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
Jasper Therapeutics, Inc. (JSPR)United States$0.020B-0.37
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B